The impact of paclitaxel and carboplatin chemotherapy on the autonomous nervous system of patients with ovarian cancer

被引：0
|
作者：
Emmanouil V. Dermitzakis
Vasilios K. Kimiskidis
George Lazaridis
Zoi Alexopoulou
Eleni Timotheadou
Alexandros Papanikolaou
Ourania Romanidou
George Georgiadis
Konstantine T. Kalogeras
Iakovos Tsiptsios
Basil Tarlatzis
George Fountzilas
机构：
[1] “Papageorgiou” Hospital,Laboratory of Clinical Neurophysiology, Department of Neurology
[2] Aristotle University of Thessaloniki,Laboratory of Clinical Neurophysiology
[3] Faculty of Medicine,Department of Medical Oncology, School of Health Sciences, Faculty of Medicine
[4] “Papageorgiou” Hospital,Department of Biostatistics
[5] Aristotle University of Thessaloniki,First Department of Obstetrics and Gynecology, School of Health Sciences, Faculty of Medicine
[6] Health Data Specialists Ltd,Neurological Department
[7] “Papageorgiou” Hospital,Laboratory of Molecular Oncology
[8] Aristotle University of Thessaloniki,undefined
[9] “Hippocration” General Hospital,undefined
[10] Hellenic Foundation for Cancer Research/Aristotle University of Thessaloniki,undefined
[11] Translational Research Section,undefined
[12] Hellenic Cooperative Oncology Group,undefined
[13] Data Office,undefined
来源：
BMC Neurology | / 16卷
关键词：
30/15 ratio; Autonomous nervous system; Orthostatic hypotension; Paclitaxel; Sympathetic skin response;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Paclitaxel plus carboplatin in the treatment of ovarian cancer
    Ozols, RF
    SEMINARS IN ONCOLOGY, 1999, 26 (01) : 84 - 89
  • [32] Consolidative abdominopelvic radiotherapy after surgery and carboplatin/paclitaxel chemotherapy for epithelial ovarian cancer
    Dinniwell, R
    Lock, M
    Pintilie, M
    Fyles, A
    Laframboise, S
    Depetrillo, D
    Levin, W
    Manchul, L
    Murphy, J
    Oza, A
    Rosen, B
    Sturgeon, J
    Milosevic, M
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 62 (01): : 104 - 110
  • [33] Phase II study of the combination carboplatin and paclitaxel in patients with ovarian cancer
    Huinink, WWT
    vanWarmerdam, LJC
    Helmerhorst, TJ
    Schaefers, MCW
    Beijnen, JH
    Rodenhuis, S
    ANNALS OF ONCOLOGY, 1997, 8 (04) : 351 - 354
  • [34] Ovarian cancer chemotherapy: carboplatin as standard
    Tattersall, MHN
    LANCET, 2002, 360 (9332): : 500 - 501
  • [35] Nedaplatin and paclitaxel comparedwith carboplatin and paclitaxel for patients with platinum-sensitive recurrent ovarian cancer
    Ge, L.
    Li, N.
    Wu, L. Y.
    GYNECOLOGIC ONCOLOGY, 2018, 149 : 33 - 34
  • [36] Nedaplatin and paclitaxel compared with carboplatin and paclitaxel for patients with platinum-sensitive recurrent ovarian cancer
    Ge, Li
    Li, Ning
    Yuan, Guang-Wen
    Sun, Yang-Chun
    Wu, Ling-Ying
    AMERICAN JOURNAL OF CANCER RESEARCH, 2018, 8 (06): : 1074 - 1082
  • [37] The safety and efficacy of weekly paclitaxel and cisplatin chemotherapy for patients with ovarian cancer who developed carboplatin hypersensitivity reaction in previous chemotherapy.
    Nishikimi, Kyoko
    Tate, Shinichi
    Matsuoka, Ayumu
    Shozu, Makio
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [38] Paclitaxel-carboplatin chemotherapy does not cause encephalopathy in patients with ovarian cancer: A prospective EEG mapping study in 28 patients
    Mayerhofer, K
    Bodner, K
    Saletu, B
    Bodner-Adler, B
    Anderer, P
    Hefler, L
    Schindl, M
    Kaider, A
    Leodolter, S
    Kainz, C
    ANTICANCER RESEARCH, 2001, 21 (1B) : 803 - 808
  • [39] Impact of obesity on chemotherapy dosing of carboplatin and survival of women with ovarian cancer
    Alexandra L. Martin
    Christelle M. Colin-Leitzinger
    Sweta K. Sinha
    Jing-Yi Chern
    Lauren C. Peres
    British Journal of Cancer, 2023, 128 : 2236 - 2242
  • [40] Impact of obesity on chemotherapy dosing of carboplatin and survival of women with ovarian cancer
    Martin, Alexandra L.
    Colin-Leitzinger, Christelle M.
    Sinha, Sweta K.
    Chern, Jing-Yi
    Peres, Lauren C.
    BRITISH JOURNAL OF CANCER, 2023, 128 (12) : 2236 - 2242
12345